Citations

Clear

3042 citation(s) found for "Kumar, S".

Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer
Hampras, Shalaka , Sucheston‐Campbell, Lara, Cannioto, Rikki , Chang‐Claude, Jenny , Dörk, Thilo , Hillemanns, Peter , Preus, Leah, Knutson, Keith L. , Wallace, Paul K. , Friel, Grace , Davis, Warren , Nesline, Mary , Pearce, Celeste Leigh, Kelemen, Linda E. , Goodman, Marc T. , Terry, Kathryn L. , Schoof, Nils , Eng, Kevin H., Clay‐Gilmour, Alyssa , Joseph, Janine M. , Aben, Katja K.H. , Antonenkova, Natalia, Baker, Helen , Bean, Yukie T., Beckmann, Matthias W. , Bisogna, Maria, Bogdanova, Natalia , Brinton, Louise A. , Bruinsma, Fiona , Campbell, Ian , Carty, Karen , Dansonka‐Mieszkowska, Agnieszka , Despierre, Evelyn, Dicks, Ed , Easton, Doug , Eccles, Diana , Edwards, Robert P., Ekici, Arif B. , Fasching, Peter A. , Gao, Yu‐Tang , Harrington, Patricia, Harter, Philipp , Hasmad, Hanis Nazihah, Hein, Alexander , Heitz, Florian , Hildebrandt, Michelle A.T., Høgdall, Claus , Høgdall, Estrid , Hosono, Satoyo , Iversen, Edwin S., Jakubowska, Anna , Jensen, Allan , Ji, Bu‐Tian , Kellar, Melissa, Kelley, Joseph L., Kiemeney, Lambertus A. , Klapdor, Rüdiger , Kolomeyevskaya, Nonna, Krakstad, Camilla , Kruszka, Bridget, Kupryjańczyk, Jolanta , Lambrechts, Diether , Lambrechts, Sandrina, Le, Nhu D. , Lee, Alice W. , Lele, Shashikant , Leminen, Arto, Lester, Jenny, Levine, Douglas A. , Liang, Dong , Lissowska, Jolanta , Liu, Song , Lu, Karen, Lubiński, Jan , Lundvall, Lene, Massuger, Leon F.A.G. , Matsuo, Keitaro , McGuire, V., McLaughlin, John R., McNeish, Iain A. , Menon, Usha , Moes-Sosnowska, Joanna , Narod, Steven A., Nedergaard, Lotte , Nickels, Stefan , Olson, Sara H. , Weber, Rachel Palmieri , Paul, James , Pelttari, Liisa M. , Perkins, Barbara, Permuth‐Wey, Jenny, Pike, Malcolm C., Plisiecka-Hałasa, Joanna, Rossing, Mary Anne, Rothstein, Joseph H. , Runnebaum, Ingo B. , Rzepecka, Iwona K. , Salvesen, Helga B., Schernhammer, Eva , Schmitt, Kristina, Schwaab, Ira, Shvetsov, Yurii B. , Sieh, Weiva , Song, Honglin , Southey, Melissa C. , Tangen, Ingvild L. , Teo, Soo‐Hwang , Thompson, Pamela J., Timorek, Agnieszka, Tworoger, Shelley S. , Altena, Anna M. van, Vergote, Ignace , Vierkant, Robert A. , Walsh, Christine , Wang‐Gohrke, Shan , Wentzensen, Nicolas, Whittemore, Alice S. , Wicklund, Kristine G. , Wu, Anna H. , Wu, Xifeng , Woo, Yin Ling , Zheng, Wei , Gayther, Simon A. , Ramus, Susan J. , Sellers, Thomas A. , Schildkraut, Joellen M. , Phelan, Catherine M., Chenevix‐Trench, Georgia , Cunningham, Julie M. , Ness, Roberta B., Odunsi, Kunle , Goode, Ellen L. , Moysich, Kirsten B., Lu, Karen H. , Lambrechts, Diether , Modugno, Francesmary , Knutson, Keith L. , Hong, Chi‐Chen , Bandera, Elisa V. , Singh, Prashant Kumar , Anton‐Culver, Hoda , Bjørge, Line , Brooks‐Wilson, Angela , Bützow, Ralf C. , Cook, Linda S. , Cramer, Daniel W. , Cybulski, Cezary , Dennis, Joe , Doherty, Jennifer A. , Bois, Andreas du , Dürst, Matthias , Fridley, Brooke L. , Gentry‐Maharaj, Aleksandra , Giles, Graham G. , Glasspool, Rosalind , Gronwald, Jacek , Hildebrandt, Michelle A.T. , Karlan, Beth Y. , Kjær, Susanne K. , Lu, Karen, McLaughlin, John R., Nevanlinna, Heli , Orlow, Irene , Pejovic, Tanja B. , Poole, Elizabeth M. , Risch, Harvey A. , Rudolph, Anja , Shu, Xiao‐Ou , Siddiqui, Nadeem , Tyrer, Jonathan P. , Wentzensen, Nicolas , Wilkens, Lynne R. , Yang, Hannah , Ziogas, Argyrios , Berchuck, Andrew , Pharoah, Paul D.P. , Pelttari, L M , Dörk, Thilo , Lambrechts, Diether , Kiemeney, Lambertus A , McNeish, Iain A , Ramus, Susan J , Teo, Soo H , Tworoger, Shelley S , Hein, Alexander , Hillemanns, Peter , Jensen, Allan , Vierkant, Robert A , Eccles, Diana , Menon, Usha , Paul, James , Moysich, Kirsten , Lissowska, Jolanta , Campbell, Ian G , Southey, Melissa C , Matsuo, Keitaro , Heitz, Florian , Jakubowska, Anna , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , Ekici, Arif B , Bogdanova, Natalia V , Chenevix-Trench, Georgia , Zheng, Wei , Høgdall, Estrid , Høgdall, Claus K , Lubinski, Jan , Goodman, Marc T

Mayo Clinic

Oncotarget | July 6, 2016 | Volume: 7 | Issue: 43 | Pages: 69097-69110

10.18632/oncotarget.10215 | PMID 27533245 Get It

Race or Resource? BMI, Race, and Other Social Factors as Risk Factors for Interlimb Differences among Overweight Breast Cancer Survivors with Lymphedema
Dean, Lorraine T. , Kumar, Anagha , Herling, Matthew, Zhang, Zi , Evangelisti, M. I., Hackley, Renata, Troxel, Andrea B. , Schwartz, J. Sanford, Schmitz, Kathryn H. , Kim, Tae‐Hoon , Brown, Justin C. , Kim, Jiyoung , Cheville, Andrea , Schmitz, Kathryn H

Mayo Clinic

Journal of Obesity | June 29, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-9

10.1155/2016/8241710 | PMID 27433356 Get It

Introduction. High BMI is a risk factor for upper body breast cancer-related lymphedema (BCRL) onset. Black cancer survivors are more likely to have high BMI than White cancer survivors. While observational analyses suggest up to 2.2 times increased risk of BCRL onset for Black breast cancer survivors, no studies have explored race or other social factors that may affect BCRL severity, operationalized by interlimb volume difference (ILD).Materials and Methods. ILD was measured by perometry for 296 overweight (25 > BMI < 50) Black (n=102) or White (n=194) breast cancer survivors (>6 months from treatment) in the WISER Survivor trial. Multivariable linear regression examined associations between social and physical factors and ILD.Results. Neither Black race (−0.26,p=0.89) nor BMI (0.22,p=0.10) was associated with ILD. Attending college (−4.89,p=0.03) was the strongest factor associated with ILD, followed by having more lymph nodes removed (4.75,p=0.01), >25% BCRL care adherence (4.10,p=0.01), and years since treatment (0.55,p<0.001).Discussion. Neither race nor BMI was associated with ILD among overweight cancer survivors. Education, a proxy for resource level, was the strongest factor associated with greater ILD. Tailoring physical activity and weight loss interventions designed to address BCRL severity by resource rather than race should be considered.
AMP-Activated Protein Kinase Suppresses Autoimmune Central Nervous System Disease by Regulating M1-Type Macrophage–Th17 Axis
Mangalam, Ashutosh K. , Rattan, Ramandeep , Suhail, Hamid, Singh, Jaspreet , Hoda, Md Nasrul, Fulzele, Sadanand , Denic, Alexander, Shridhar, Viji, Viollet, Benoı̂t , Rodriguez, Moses , Giri, Shailendra , Đenić, Aleksandar , Viollet, Benoit , Giri, Shailendra , Deshpande, Mandar , Denic, Alexander, Shridhar, Viji , Kumar, Ashok , Denic, Aleksandar , Rodriguez, Moses

Mayo Clinic

The Journal of Immunology | June 29, 2016 | Volume: 197 | Issue: 3 | Pages: 747-760

10.4049/jimmunol.1501549 | PMID 27354217 Get It

Abstract The AMP-activated protein kinase, AMPK, is an energy-sensing, metabolic switch implicated in various metabolic disorders; however, its role in inflammation is not well defined. We have previously shown that loss of AMPK exacerbates experimental autoimmune encephalomyelitis (EAE) disease severity. In this study, we investigated the mechanism through which AMPK modulates inflammatory disease like EAE. AMPKα1 knockout (α1KO) mice with EAE showed severe demyelination and inflammation in the brain and spinal cord compared with wild-type due to higher expression of proinflammatory Th17 cytokines, including IL-17, IL-23, and IL-1β, impaired blood–brain barrier integrity, and increased infiltration of inflammatory cells in the CNS. Infiltrated CD4 cells in the brains and spinal cords of α1KO with EAE were significantly higher compared with wild-type EAE and were characterized as IL-17 (IL-17 and GM-CSF double-positive) CD4 cells. Increased inflammatory response in α1KO mice was due to polarization of macrophages (Mϕ) to proinflammatory M1 type phenotype (IL-10lowIL-23/IL-1β/IL-6high), and these M1 Mϕ showed stronger capacity to induce allogenic as well as Ag-specific (myelin oligodendrocyte glycoprotein [MOG]35–55) T cell response. Mϕ from α1KO mice also enhanced the encephalitogenic property of MOG35–55–primed CD4 T cells in B6 mice. The increased encephalitogenic MOG-restricted CD4+ T cells were due to an autocrine effect of IL-1β/IL-23–mediated induction of IL-6 production in α1KO Mϕ, which in turn induce IL-17 and GM-CSF production in CD4 cells. Collectively, our data indicate that AMPK controls the inflammatory disease by regulating the M1 phenotype–Th17 axis in an animal model of multiple sclerosis.
Induction therapy pre‐autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation
Hwa, Yi L. , Kumar, Shaji , Lacy, Martha Q. , Kourelis, Taxiarchis , Kapoor, Prashant , Dingli, David , Kyle, Robert A. , Russell, Stephen J. , Lust, John A., Hayman, Suzanne R. , Lin, Yi , Zeldenrust, Steven R., Dispenzieri, Angela , Buadi, Francis K. , Kourelis, Taxiarchis V, Russell, Stephen, Zeldenrust, Steven, Gertz, Morie A. , Gonsalves, Wilson I. , Rajkumar, S. Vincent , Go, Ronald S. , Leung, Nelson , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Lin, Yi

Mayo Clinic

American Journal of Hematology | June 24, 2016 | Volume: 91 | Issue: 10 | Pages: 984-988

10.1002/ajh.24453 | PMID 27341539 Get It

There is no consensus on whether patients with immunoglobulin light chain amyloidosis (AL) should receive induction therapy prior to an autologous stem cell transplant (ASCT). This study investigated the relationships between baseline bone marrow plasmacytosis (BMPC), cardiac staging, and pre‐transplant induction in AL patients. All patients who received ASCT for AL within 12 months of diagnosis were included. Patient characteristics and outcomes were abstracted. Univariate and multivariate modeling was performed. Among 415 AL patients, 35% had induction prior to ASCT. Post‐ASCT hematologic CR plus VGPR rates were significantly higher in those with baseline BMPC ≤ 10% compared to BMPC >10% (58% versus 40%, P = 0.0013). Significant risk factors for lack of attainment of CR included attenuated dose melphalan conditioning, baseline BMPC > 10%, no induction, and male gender. The 5‐year OS for the entire group was 65%. On multivariate analysis, risk factors for inferior OS included no induction therapy, advanced AL amyloid staging, BMPC > 10%, attenuated conditioning melphalan dose, and male gender. Patients with Mayo 2012 stage I–II patients with BMPC ≤ 10%, who comprised 56% of the ASCT population fared exceedingly well regardless of whether or not they received induction therapy with a 5‐year OS of 81 to 83%. Induction therapy pre‐ASCT may improve outcomes among AL patients due to a rapid reduction of toxic light chains or alternatively by elimination of less fit patients by “testing” their ability to tolerate chemotherapy. Prospective studies will be required to sort out these and other questions. Am. J. Hematol. 91:984–988, 2016. © 2016 Wiley Periodicals, Inc.
Durability of Addition of Roux-en-Y Gastric Bypass to Lifestyle Intervention and Medical Management in Achieving Primary Treatment Goals for Uncontrolled Type 2 Diabetes in Mild to Moderate Obesity: A Randomized Control Trial
Ikramuddin, Sayeed , Körner, Judith , Bantle, John P., Thomas, Avis J., Connett, John E. , Leslie, Daniel B. , Inabnet, William B. , Wang, Qi , Jeffery, Robert W., Chong, Keong , Chuang, Lee‐Ming , Jensen, Michael D. , Ahmed, Leaque , Belani, Kumar G. , Olofson, Amy , Bainbridge, Heather A., Olofson, Amy E, Lee, Wei‐Jei , Vella, Adrian , Billington, Charles J.

Mayo Clinic

Diabetes Care | June 17, 2016 | Volume: 39 | Issue: 9 | Pages: 1510-1518

10.2337/dc15-2481 | PMID 27311493 Get It

OBJECTIVE We compared 3-year achievement of an American Diabetes Association composite treatment goal (HbA1c &lt;7.0%, LDL cholesterol &lt;100 mg/dL, and systolic blood pressure &lt;130 mmHg) after 2 years of intensive lifestyle-medical management intervention, with and without Roux-en-Y gastric bypass, with one additional year of usual care. RESEARCH DESIGN AND METHODS A total of 120 adult participants, with BMI 30.0–39.9 kg/m2 and HbA1c ≥8.0%, were randomized 1:1 to two treatment arms at three clinical sites in the U.S. and one in Taiwan. All patients received the lifestyle-medical management intervention for 24 months; half were randomized to also receive gastric bypass. RESULTS At 36 months, the triple end point goal was met in 9% of lifestyle-medical management patients and 28% of gastric bypass patients (P = 0.01): 10% and 19% lower than at 12 months. Mean (SD) HbA1c values at 3 years were 8.6% (3.5) and 6.7% (2.0) (P &lt; 0.001). No lifestyle-medical management patient had remission of diabetes at 36 months, whereas 17% of gastric bypass patients had full remission and 19% had partial remission. Lifestyle-medical management patients used more medications than gastric bypass patients: mean (SD) 3.8 (3.3) vs. 1.8 (2.4). Percent weight loss was mean (SD) 6.3% (16.1) in lifestyle-medical management vs. 21.0% (14.5) in gastric bypass (P &lt; 0.001). Over 3 years, 24 serious or clinically significant adverse events were observed in lifestyle-medical management vs. 51 with gastric bypass. CONCLUSIONS Gastric bypass is more effective than lifestyle-medical management intervention in achieving diabetes treatment goals, mainly by improved glycemic control. However, the effect of surgery diminishes with time and is associated with more adverse events.
Quantification of lipid modified estrogenic derivative (ESC8) in rat plasma by LC‐MS: application to a pharmacokinetic study
Ahmad, Ajaz , Mondal, Sujan Kumar , Jan, Basit Latief, Banerjee‬‬‬‬‬‬‬‬‬, Rintu , Alkharfy, Khalid M. , Jan, Basit L. , Mukhopadhyay, Debabrata , Banerjee, Rajkumar

Mayo Clinic

Biomedical Chromatography | June 16, 2016 | Volume: 30 | Issue: 12 | Pages: 2024-2030

10.1002/bmc.3780 | PMID 27306429 Get It

AbstractA lipid‐conjugated, estrogenic derivative molecule, ESC8, compared with other estrogenic molecules, encourages cell death in both ER‐positive and ER‐negative breast cancer cells. A rapid and highly sensitive assay method has been developed and validated for the estimation of a ESC8 in rat plasma using liquid chromatography coupled with mass spectrometry under positive‐ion mode with electrospray ionization. The sample process includes using methanol for precipitation of ESC8 and dextromethorphan (internal standard, IS) from plasma. Chromatographic separation was achieved with methanol–water–formic acid (70:30:0.1% v/v/v) pumped at a flow rate of 0.3mL/min and a C18 column (50 × 2.1 mm i.d., 1.7 μm particle size) with a total run time of 5 min. The m/z ions monitored were 568.5 and 272.1 for ESC8 and IS, respectively. The lower limit of quantitation achieved was 1.08 ng/mL and linearity was observed from 5 to 500 ng/mL. The intra‐ and inter‐day precisions were <4%. The proposed method was successfully applied to a preliminary pharmacokinetic study of ESC8 liposomal formulation following an intraperitoneal administration of 3.67 mg/kg in rats. The concentrations of ESC8 in plasma were quantifiable up to 36 h. The peak concentration of ESC8 was found to be 110.72 ng/mL, the area under the concentration–time curve was 1625.23ng/mL h and the half‐life was 11.72 h.
The effect of an automated point of care tool on diagnosis and management of childhood obesity in primary care
Gentile, Natalie, Cristiani, Valeria, Lynch, Brian , Wilson, Patrick M. , Weaver, Amy L. , Jacobson, Debra J., Chaudhry, Rajeev , Sriram, Swetha, Kumar, Seema , Lynch, Brian A, Rutten, Lila J, Rutten, Lila J. Finney

Mayo Clinic

Journal of Evaluation in Clinical Practice | June 10, 2016 | Volume: 22 | Issue: 6 | Pages: 962-968

10.1111/jep.12572 | PMID 27282887 Get It

AbstractBackgroundChildhood obesity is underdiagnosed in primary care practices. Our study aimed to compare rates of documentation of diagnosis of obesity and counselling for nutrition and physical activity at an academic primary care practice prior to and following implementation of a body mass index (BMI)‐based electronic point of care clinical reminder tool.MethodsWe performed a retrospective record review of children aged 2–18 years undergoing well child visits during any of three calendar years (2009, 2011 and 2013). The electronic clinical reminder tool was implemented in September 2010. Records of children with BMI > 95th percentile were electronically searched for terms of documentation of diagnosis of obesity and nutrition and physical activity counselling. Multivariable logistic regression models were used to adjust for potential patient and provider confounders.ResultsAmong those with BMI ≥ 95th percentile, there was a statistically significant increase in documentation of diagnosis of obesity (45.5% in 2009 vs. 52.4% in 2011; P < 0.001; adjusted odds ratio 1.36; 95% CI 1.13–1.65) and in counselling for physical activity and nutrition (66.8% in 2009 vs. 75.2% in 2011; P < 0.001; adjusted odds ratio 1.33; 95% CI 1.06–1.66) following implementation of the tool. Compared with 2011, there was no statistically significant increase in documentation of obesity (50.4%) or nutrition and physical activity counselling (77.9%) in 2013.ConclusionsThe implementation of a point of care clinical reminder tool was associated with improvement in documentation of diagnosis of obesity and counselling for nutrition and physical activity. Further studies are needed to determine the impact of these automated tools on weight outcomes in children.
Patterns and predictors of clustered risky health behaviors among adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study
Lown, E. Anne , Zhang, Nan , Srivastava, Deo Kumar , Leisenring, Wendy M. , Nathan, Paul C. , Devine, Katie A. , Krull, Kevin R. , Oeffinger, Kevin C. , Armstrong, Gregory T. , Ness, Kirsten K. , Hijiya, Nobuko , Castellino, Sharon M. , Dilley, Kimberley Jo , Hudson, Melissa M. , Robison, Leslie L. , Leisenring, Wendy , Ness, Kirsten K

Mayo Clinic

Cancer | June 3, 2016 | Volume: 122 | Issue: 17 | Pages: 2747-2756

10.1002/cncr.30106 | PMID 27258389 Get It

BACKGROUNDHealth complications related to childhood cancer may be influenced by risky health behaviors (RHBs), particularly when RHBs co‐occur. To the authors' knowledge, only limited information is available describing how RHBs cluster among survivors of childhood cancer and their siblings and the risk factors for co‐occurring RHBs.METHODSLatent class analysis was used to identify RHB clusters using longitudinal survey data regarding smoking, alcohol use, and physical activity from adult survivors (4184 survivors) and siblings (1598 siblings) in the Childhood Cancer Survivor Study. Generalized logistic regression was used to evaluate associations between demographic characteristics, treatment exposures, psychological distress, health conditions, and cluster membership.RESULTSThree RHB clusters were identified: a low‐risk cluster, an insufficiently active cluster, and a high‐risk cluster (tobacco and risky alcohol use and insufficient activity). Compared with siblings, survivors were more likely to be in the insufficiently active cluster (adjusted odds ratio [ORadj], 1.17; 95% confidence interval [95% CI], 1.06‐1.27) and were less likely to be in the high‐risk cluster (ORadj, 0.79; 95% CI, 0.69‐0.88). Risk factors for membership in the high‐risk cluster included psychological distress (ORadj, 2.76; 95% CI, 1.98‐3.86), low educational attainment (ORadj, 7.49; 95% CI, 5.15‐10.88), income <$20,000 (ORadj, 2.62; 95% CI, 1.93‐3.57), being divorced/separated or widowed (ORadj, 1.36; 95% CI, 1.03‐1.79), and limb amputation (ORadj, 1.52; 95% CI, 1.03‐2.24). Risk factors for the insufficiently active cluster included chronic health conditions, psychological distress, low education or income, being obese or overweight, female sex, nonwhite race/ethnicity, single marital status, cranial radiation, and cisplatin exposure.CONCLUSIONSRHBs co‐occur in survivors of childhood cancer and their siblings. Economic and educational disadvantages and psychological distress should be considered in screening and interventions to reduce RHBs. Cancer 2016. © 2016 American Cancer Society. Cancer 2016;122:2747–2756. © 2016 American Cancer Society.
Characterization and use of HapT1-derived homologous tumors as a preclinical model to evaluate therapeutic efficacy of drugs against pancreatic tumor desmoplasia
Suklabaidya, Sujit , Das, Biswajit , Ali, Syed Azmal , Swaminathan, Sharada , Mohanty, Ashok Kumar , Panda, Susen Kumar , Dash, Pujarini , Chakraborty, Subhankar , Senapati, Shantibhusan , Jain, Sumeet , Batra, Surinder K.

Mayo Clinic

Oncotarget | May 31, 2016 | Volume: 7 | Issue: 27 | Pages: 41825-41842

10.18632/oncotarget.9729 | PMID 27259232 Get It